Formulation and Evaluation of Cefixime Pediatric Medicated Lollipops

The study explores the formulation and evaluation of Cefixime medicated lollipops as a novel solution for paediatric oral drug delivery. The developed lollipops demonstrated desirable physical and pharmaceutical attributes, including consistent drug content, optimal hardness, and adherence to weight variation standards. Fourier-transform infrared spectroscopy confirmed the absence of significant drug-excipient interactions, ensuring formulation stability. Among the tested formulations, F2 exhibited the most promising results, achieving 100.05% cumulative drug release within 15 minutes during In vitro dissolution studies. Stability assessments over three months under accelerated conditions confirmed the lollipops' physical and chemical integrity, with drug content remaining within acceptable limits.This innovative dosage form addresses common challenges in pediatric drug administration by enhancing palatability, simplifying administration, and improving patient compliance. Additionally, the reduced dosing frequency associated with the formulation offers practical advantages for paediatric care. These findings position Cefixime medicated lollipops as a patient-friendly and efficient alternative to conventional paediatric dosage forms. It is recommended that further clinical studies be conducted to determine their effectiveness and safety in real-world paediatric settings.